IRC Section 174

Internal Revenue Code Section 174 establishes the federal standards for the treatment of research and experimental expenditures, mandating capitalization over five or fifteen years unless specifically superseded by state-level decoupling or newly enacted federal expensing provisions. In the New Jersey tax landscape, the state permits a current-year deduction for these otherwise capitalized costs provided the taxpayer claims a New Jersey research and development tax credit, effectively aligning state incentives with the immediate liquidity needs of innovative enterprises.

The relationship between federal tax policy under IRC Section 174 and state-level incentives in New Jersey represents one of the most complex intersections of fiscal law currently facing corporate taxpayers. For decades, Section 174 allowed businesses to immediately deduct research and experimental (R&E) expenditures, a policy designed to lower the barrier to entry for innovation-led growth. However, the enactment of the Tax Cuts and Jobs Act (TCJA) of 2017 introduced a mandatory capitalization and amortization regime for tax years beginning after December 31, 2021. This shift fundamentally altered the cash-flow dynamics of technology and life sciences firms, as it required them to recognize higher taxable income in the short term by spreading deductions over a five-year period for domestic research and a fifteen-year period for foreign research. In response to this federal shift, New Jersey enacted targeted legislation through Assembly Bill 5323 (A.B. 5323) to selectively decouple from the federal amortization requirements, but only for those taxpayers who actively participate in the state’s research and development credit program. This creates a conditional tax environment where the timing of a deduction is inextricably linked to the claiming of a credit, necessitating a high degree of precision in tax planning and documentation.

The Evolution of IRC Section 174 and the Emergence of Section 174A

The historical trajectory of IRC Section 174 reveals a persistent tension between the government’s desire to stimulate innovation and its requirement to maintain a stable tax base. From 1954 through 2021, the prevailing standard was one of flexibility, allowing taxpayers to choose between immediate expensing and deferred amortization. This flexibility was removed by the TCJA, which sought to offset other corporate tax cuts by lengthening the recovery period for R&D investments.

The mandate to capitalize and amortize R&E expenditures over five years (domestic) or fifteen years (foreign) was particularly burdensome because it expanded the definition of R&E to explicitly include all software development costs. Taxpayers were forced to re-categorize a vast array of operational expenses into the Section 174 bucket, often discovering that their federal taxable income rose significantly without a corresponding increase in actual cash profits. This was compounded by the fact that Section 174(d) generally prohibits the immediate recovery of unamortized basis in foreign capitalized research even upon the disposition or abandonment of the underlying property, further trapping costs in long-term amortization schedules.

The legislative pendulum swung back toward expensing with the passage of the One Big Beautiful Bill Act (OBBBA) on July 4, 2025. This landmark legislation introduced a new IRC Section 174A, which permanently restores the ability of taxpayers to fully expense domestic R&E expenditures paid or incurred in taxable years beginning after December 31, 2024. While Section 174A provides relief for future expenditures, the OBBBA also addresses the “TCJA gap years” of 2022 through 2024 by providing transition rules that allow for the acceleration of unamortized domestic research costs.

Legislative Era	Provision	Domestic R&E Treatment	Foreign R&E Treatment
Pre-2022	Section 174	Immediate Expensing or 60-month Amortization	Immediate Expensing or 60-month Amortization
2022 – 2024 (TCJA)	Section 174	Mandatory 5-year Amortization (Half-year convention)	Mandatory 15-year Amortization (Half-year convention)
2025+ (OBBBA)	Section 174A	Full Expensing (Permanent)	Mandatory 15-year Amortization (Permanent)
2025+ (OBBBA)	Section 174A(c)	Elective Amortization (Min. 60 months)	N/A

The restoration of expensing under Section 174A is not a total repeal of the TCJA regime. Critically, foreign research activities remain subject to the fifteen-year amortization requirement, reinforcing a “buy American” innovation policy. Furthermore, the OBBBA introduces a small business retroactive relief provision, allowing companies with average annual gross receipts of $31 million or less to amend their 2022, 2023, and 2024 returns to claim immediate deductions for domestic research, a move designed to inject capital into the startup ecosystem.

New Jersey’s Legislative Response: Assembly Bill 5323

As a rolling-conformity state, New Jersey generally adopts the Internal Revenue Code as it is currently amended. When the federal mandate to capitalize research expenses took effect in 2022, New Jersey corporate taxpayers were initially required to follow the same amortization schedule for the state’s Corporation Business Tax (CBT). Recognizing the potential competitive disadvantage this posed for the state’s high-tech clusters in regions like Princeton and Newark, the New Jersey Legislature enacted A.B. 5323 (P.L. 2023, c. 96) in July 2023.

This legislation provided a retroactive fix for privilege periods ending on or after July 31, 2022. The core mechanism of A.B. 5323 is the modification of the state’s decoupling from Section 174. Specifically, New Jersey now allows a current-year deduction for research and experimental expenses incurred during the same privilege period for which a New Jersey research and development credit is claimed. This creates a high-stakes linkage: if a taxpayer identifies New Jersey qualified research expenditures (QREs) and claims the credit on Form 306, the state effectively “ignores” the federal capitalization requirement for those specific New Jersey costs and allows an immediate deduction.

However, the decoupling is conditional and partial. If a taxpayer does not claim a New Jersey R&D credit—perhaps because their research was conducted outside of New Jersey or because they do not meet the qualification threshold—the state remains in conformity with federal law. For the 2022-2024 period, this meant such taxpayers were still required to capitalize and amortize their domestic research for CBT purposes. This underscores the importance of the “geographic nexus” of the research; only research conducted within New Jersey triggers the credit, and only the credit triggers the decoupling.

Mechanics of the New Jersey R&D Tax Credit (N.J.S.A. 54:10A-5.24)

The New Jersey Research and Development Tax Credit is governed by N.J.S.A. 54:10A-5.24 and is designed to reward businesses for conducting qualified research activities within the state boundaries. The credit is calculated using two primary components: qualified research expenses and basic research payments.

Calculation Methodology

The credit amount is generally equal to:

1. 10% of the excess of qualified research expenses (QREs) for the privilege period over the base amount.
2. 10% of the basic research payments for the privilege period.

The “base amount” calculation depends on whether the taxpayer elects the Regular Credit method or the Alternative Simplified Credit (ASC) method. Since 2018, New Jersey law mandates consistency: if a taxpayer uses the ASC method on their federal Form 6765, they must also use the ASC method for their New Jersey Form 306.

Component	Standard Credit (Regular)	Alternative Simplified Credit (ASC)
QRE Inclusion	Wages, supplies, computer leasing, 65% of contract research	Wages, supplies, computer leasing, 65% of contract research
Base Amount	Fixed-base % x avg. prior 4 years’ gross receipts	50% of avg. QREs for prior 3 years
Credit Rate	10% of excess	10% of excess
Basic Research	10% of payments to universities/energy consortia	10% of payments to universities/energy consortia

The formula for the New Jersey R&D credit can be expressed as:

$$C_{NJ} = 0.10 \times (QRE_{curr} – B_{NJ}) + 0.10 \times P_{basic}$$

Where $C_{NJ}$ is the total New Jersey credit, $QRE_{curr}$ represents New Jersey qualified research expenses in the current year, $B_{NJ}$ is the New Jersey-specific base amount, and $P_{basic}$ represents basic research payments made to New Jersey organizations.

Qualified Research Expenditures (QREs)

To qualify for the credit and the subsequent Section 174 decoupling, expenditures must meet the federal four-part test defined in IRC Section 41(d). The activities must be:

• Technological in Nature: Grounded in the physical, biological, or computer sciences.
• Permitted Purpose: Intended to create a new or improved business component’s function, performance, reliability, or quality.
• Elimination of Uncertainty: Designed to discover information that resolves uncertainty regarding the capability, method, or design of a product or process.
• Process of Experimentation: Involving a systematic evaluative process, such as modeling, simulation, or trial and error, to resolve technical uncertainties.

In the New Jersey context, these costs must be “tied to New Jersey activities”. Wages must be paid to employees performing or supporting research physically located in the state, and supplies must be consumed in New Jersey-based experimentation. This geographic restriction is the primary friction point for multi-state corporations, as federal Section 174 capitalization applies to all domestic costs, but New Jersey decoupling only applies to the subset of those costs that qualify for the state credit.

State Administrative Guidance: Decoding Technical Bulletin 114 (TB-114)

The New Jersey Division of Taxation provides the administrative framework for these laws through Technical Bulletins, specifically TB-114 (Revised November 25, 2025). This guidance is critical for tax professionals as it clarifies the Division’s interpretation of how the state’s CBT and Gross Income Tax (GIT) interact with federal law changes.

The Integration of Federal Rules

TB-114 explicitly states that federal rules and case law on IRC Section 174 (or the new 174A) and IRC Section 41 are applicable for New Jersey purposes unless state statutory limitations differ. This means that the IRS’s detailed guidance on software development—such as Notice 2023-63 and Notice 2024-12—is essentially incorporated into New Jersey’s tax code. If the IRS deems a certain activity “software development” for the purpose of Section 174, New Jersey will follow that classification.

The Decoupling Mechanism in Practice

The Division clarifies that taxpayers claiming the CBT R&D credit can “also deduct those New Jersey expenditures on their tax return in the same year as they claim the credit, rather than amortizing the expenditures”. This provides a definitive “check” for compliance: a taxpayer must file Form 306 alongside their Form CBT-100 to qualify for the immediate deduction of 2022-2024 costs.

TB-114 also addresses the treatment of federal adjustments. If the IRS amends a taxpayer’s federal return—for instance, by reclassifying Section 162 ordinary business expenses as Section 174 research costs—this does not automatically change the New Jersey R&D credit unless those expenses were for research conducted in New Jersey. This highlights the “independent yet linked” nature of the state credit; while the definitions are federal, the jurisdiction is strictly local.

Interaction with IRC Section 280C

One of the most favorable aspects of the New Jersey guidance is the treatment of IRC Section 280C(c). Under federal law, taxpayers must either reduce their R&E deduction by the amount of the credit claimed or elect a reduced credit to avoid a “double benefit”. New Jersey, however, does not require a similar add-back of the state credit amount to entire net income. This means a company can claim the 10% state credit and still deduct 100% of the qualified expenditures, resulting in an effective tax benefit that exceeds the federal equivalent.

Entity-Specific Taxation and Combined Reporting

The application of Section 174 and the R&D credit varies significantly depending on the corporate structure of the taxpayer. New Jersey’s transition to combined reporting in 2019 added a layer of complexity for unitary businesses.

Combined Groups (Form CBT-100U)

Groups of companies under common ownership engaged in a unitary business must file as a combined group. In this context:

• Credit Sharing: Credits and carryforwards can be shared among taxable members of the combined group without the need for formal transfer certificates.
• Apportionment: For combined groups, the New Jersey R&D credit is limited to research in New Jersey, and the apportionment of the group’s income is typically based on a three-factor formula of property, payroll, and receipts.
• Section 163(j): A.B. 5323 requires taxpayers to compute the IRC Section 163(j) interest deduction limitation on a New Jersey combined basis, retroactively effective for tax years beginning on or after January 1, 2022. This interacts with Section 174 because amortization and depreciation are added back to adjusted taxable income (ATI) for the interest limit calculation.

S-Corporations and Pass-Through Entities

New Jersey treats S-corporations differently than the federal government. While a federal S-corp is a pure pass-through, a New Jersey S-corp (or QSSS) pays a statutory minimum tax and claims credits only against its entity-level CBT liability.

• No Personal Credit: The New Jersey R&D credit cannot be passed through to individual shareholders via a K-1 to offset New Jersey Gross Income Tax (GIT).
• Partnerships: Credits are generally not available to partnerships or other pass-through entities directly; however, corporate partners in a partnership may claim their distributive share of the partnership’s research expenses to calculate a credit on their own CBT-100 returns.

Cannabis Licensees

New Jersey has specifically decoupled from the restrictive federal provisions of IRC Section 280E for cannabis businesses. Effective for tax years beginning on or after January 1, 2023, registered cannabis licensees filing CBT returns are eligible to treat research-related expenses as QREs for the state credit and utilize the Section 174 decoupling provisions.

Specialized Incentives: The NJEDA Monetization Programs

For early-stage technology and biotechnology firms that are not yet profitable, a tax credit that only offsets a non-existent tax liability is of limited value. To address this, New Jersey offers specialized programs through the New Jersey Economic Development Authority (NJEDA) to monetize these incentives.

The Technology Business Tax Certificate Transfer Program (NOL Program)

Unprofitable firms with fewer than 225 U.S. employees can sell their unused R&D credits and Net Operating Losses (NOLs) to other New Jersey corporate taxpayers for cash.

• Minimum Price: Certificates are sold for at least 80% of their face value.
• Lifetime Cap: There is a $20 million lifetime cap per firm.
• Economic Impact: In 2024, participating companies generated an estimated $28.1 billion in direct and indirect economic impact. Since 1999, the program has provided critical growth capital to nearly 600 companies.

Extended Carryforward and Innovation Zones

While the standard carryforward for the New Jersey R&D credit is seven years, certain “priority” industries benefit from an extended fifteen-year carryforward period. This supports the long-term R&D cycles inherent in life sciences and advanced computing. Furthermore, $15 million of the annual $75 million NOL program pool is set aside for businesses located in the state’s three Innovation Zones: Newark, Camden, and the Greater New Brunswick area.

Priority Industry Category	Standard Carryforward	Extended Carryforward
Standard CBT Filer	7 Years	N/A
Advanced Computing	7 Years	15 Years
Biotechnology	7 Years	15 Years
Environmental Tech	7 Years	15 Years
Medical Device Tech	7 Years	15 Years

Economic Statistics and the State of the Innovation Economy

The fiscal health of New Jersey and the performance of its innovation sector are reflected in recent budgetary and economic data.

Corporation Business Tax (CBT) Revenue Projections

The state’s reliance on corporate tax revenue is significant, but forecasts suggest a cooling period. The Office of Legislative Services (OLS) projects that CBT revenue will decline by 15.0% in Fiscal Year 2025, dropping to approximately $4.36 billion. This decline is influenced by the expiration of the 2.5% surtax and the shifting landscape of federal and state deductions.

The New Jersey InventionIndex

As of November 2025, the InventionIndex for New Jersey stands at 0.85%, resulting in a “D” grade. This score measures innovation output by comparing GDP growth with patent production growth. While this represents a slight improvement from the lows of late 2024 (0.68%), the state has yet to regain the momentum seen in August 2025 when the index surged to 1.47% (A+ rating). The stagnation is partly attributed to the lingering effects of the pandemic and the administrative burden of navigating the TCJA-era capitalization rules.

Research and Development Spending

In FY 2024, New Jersey accounted for $110 million in state government expenditures for extramural R&D performance, placing it among the top five states in the nation for this metric. Within the private sector, the life sciences cluster remains the most robust claimant of R&D-related benefits. For example, in 2025, the “Information” sector (including streaming and data processing) received an average of $191,000 in credits per recipient in comparable programs, demonstrating the high concentration of qualified research in technology-intensive fields.

Comprehensive Case Study: Strategic Modeling for a Technology Startup

To better understand the interaction between IRC Section 174A and the New Jersey R&D credit, we can model the tax position of a hypothetical mid-market firm during the transition from the TCJA regime to the OBBBA regime.

The Subject: Cyberspace Dynamics, Inc.

Company Profile:

• Location: Jersey City, NJ.
• Industry: Cybersecurity Software Development.
• Status: C-Corporation, profitable.
• Average Annual Gross Receipts (2022-2024): $40 million (Does not qualify for the “small business” $31M retroactive relief).

Financial Data for Tax Year 2025:

• Total Domestic R&E Costs (Section 174A): $2,500,000.
• New Jersey QREs (Conducting research in NJ): $2,000,000.
• Prior Year QREs (Avg. 2022-2024): $1,600,000.
• Unamortized 174 Costs from 2022-2024: $1,000,000.

Step 1: Federal Tax Treatment (OBBBA)

Under the new Section 174A, Cyberspace Dynamics can fully expense its 2025 domestic research costs of $2,500,000. Additionally, the company elects to accelerate its unamortized $1,000,000 from the TCJA years entirely in 2025.

• Total 2025 Federal R&E Deduction: $3,500,000.
• Federal R&D Credit (Form 6765): Calculated on $2,500,000 (Domestic research).

Step 2: New Jersey CBT Treatment

Because the company is claiming a New Jersey R&D credit, it can utilize the decoupling provision.

• NJ R&D Credit Calculation (ASC Method):
  • Base Amount = $1,600,000 / 2 = $800,000.
  • Excess QREs = $2,000,000 – $800,000 = $1,200,000.
  • NJ Credit Amount = $1,200,000 x 10% = $120,000.
• NJ Entire Net Income (ENI) Adjustment:
  • New Jersey follows the federal expensing for 2025 ($2,500,000) because of its rolling conformity and the fact that a credit was claimed.
  • The company also deducts the $1,000,000 in unamortized prior costs, as New Jersey follows federal accounting method changes.
  • No 280C Add-back: The $120,000 credit does not reduce the state deduction.

Result and Implications

Cyberspace Dynamics receives an immediate $3.5 million reduction in its New Jersey taxable income and a $120,000 direct credit against its CBT liability. If the company had not claimed the NJ credit—perhaps by failing to document that the research was in NJ—the state might have challenged the timing of the $1,000,000 catch-up deduction or the 2025 expensing depending on the specific privilege period rules.

Documentation, Audit Readiness, and Compliance

The liberalization of research expensing under the OBBBA and the state decoupling provisions does not imply a relaxation of enforcement. In fact, the IRS has introduced more stringent reporting requirements via the updated Form 6765, effective for tax year 2025.

New Federal Documentation Standards

For 2025 and beyond, taxpayers must provide:

• Business Component Detail: Information for each specific business component related to the research.
• Project-Level Breakout: A breakout of QREs by individual project.
• Wage Categories: A breakdown of wages by direct research, direct support, and direct supervision for each component.

New Jersey Statute of Limitations

Taxpayers have a four-year window to claim the New Jersey R&D credit or amend prior returns. Given the retroactive nature of A.B. 5323 for the 2022 tax year, many companies may still be within the window to file amended returns and secure refunds by claiming the credit and decoupling from federal capitalization. However, any federal adjustment by the IRS must be reported to the New Jersey Division of Taxation within 90 days to avoid penalties.

Best Practices for Professional Peers

To ensure compliance and maximize benefits, the following protocols should be implemented:

1. Gross Receipts Analysis: Review average annual receipts for the 2020-2022 period to determine if the $31 million threshold is met for retroactive small business relief.
2. Geographic Time-Tracking: Implement systems to distinguish between domestic research conducted in New Jersey versus other states to substantiate the state credit and decoupling.
3. Modeling Section 163(j): Estimate the impact of immediate expensing versus elective amortization on the interest limitation to determine the optimal overall tax position.
4. Contemporaneous Documentation: Capture the role of technical staff and link costs to specific experimentation activities throughout the tax year rather than relying on retrospective estimates.

Final Thoughts

The intersection of IRC Section 174 and the New Jersey Research and Development Tax Credit is a vital component of the state’s fiscal strategy to attract and retain high-growth industries. While the federal Tax Cuts and Jobs Act created a significant liquidity hurdle through mandatory capitalization, the subsequent enactment of the One Big Beautiful Bill Act and New Jersey’s A.B. 5323 have provided a path toward fiscal normalization. For the modern enterprise, the primary takeaway is the conditional nature of these benefits: the immediate expensing of research costs at the state level is not a right, but a reward for those who can demonstrate a tangible investment in New Jersey’s innovation ecosystem. By maintaining rigorous documentation and aligning state credit claims with federal expensing elections, businesses can significantly reduce their effective tax rate and secure the capital necessary to drive future scientific and technological progress.